UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
| (Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
As previously disclosed, on November 16, 2026, InspireMD, Inc. (the “Company”) closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and pre-funded warrants to purchase up to 50,350,000 shares of Common Stock, and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of Common Stock (the “Common Warrants”), pursuant to the Company’s effective automatic shelf registration statement on Form S-3 (File No. 333-286309) previously filed with the Securities and Exchange Commission (the “SEC”), raising approximately $34.9 million in net proceeds after deducting underwriting discounts and before offering expenses. Pursuant to the Underwriting Agreement, dated November 13, 2026 (the “Underwriting Agreement”), by and among the Company and Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), the Underwriters were granted a 30-day option (the “Option”) to purchase up to an additional 8,635,846 shares of Common Stock (the “Option Shares”) and/or Common Warrants to purchase up to 6,490,384 shares of Common Stock (the “Option Common Warrants”) from the Company on the same terms and conditions.
On November 18, 2026, the Representative notified the Company that it had elected to exercise the Option in full. The offering of the Option Shares and Option Common Warrants closed on November 20, 2026, raising an additional approximately $5.3 million in net proceeds after deducting underwriting discounts and before offering expenses.
The Option Common Warrants will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026, by and between the Company and Securities Transfer Corporation, as warrant agent.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INSPIREMD, INC. | ||
| Date: November 20, 2026 | By: | /s/ Marvin Slosman |
| Name: | Marvin Slosman | |
| Title: | Chief Executive Officer | |